JS006 is a humanized IgG4kappa monoclonal antibody inhibitor targeting TIGIT/CD155. It is applicable in the study of advanced and/or metastatic cancers, such as non-small cell lung cancer (NSCLC), advanced lymphoma, and advanced/metastatic triple-negative breast cancer (TNBC), particularly when resistance to PD-1/PD-L1 inhibitors has developed.
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
